Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Financing Activities (2019 - 2025)

Revolution Medicines has reported Cash from Financing Activities over the past 7 years, most recently at $365.7 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $365.7 million for Q4 2025, down 58.15% from a year ago — trailing twelve months through Dec 2025 was $621.5 million (down 35.22% YoY), and the annual figure for FY2025 was $621.5 million, down 35.22%.
  • Cash from Financing Activities for Q4 2025 was $365.7 million at Revolution Medicines, up from -$1.6 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for RVMD hit a ceiling of $873.8 million in Q4 2024 and a floor of -$1.6 million in Q3 2025.
  • Median Cash from Financing Activities over the past 5 years was $31.0 million (2021), compared with a mean of $170.3 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 106196.72% in 2023 and later tumbled 102.06% in 2025.
  • Revolution Medicines' Cash from Financing Activities stood at $10.7 million in 2021, then soared by 378.78% to $51.4 million in 2022, then surged by 1534.16% to $839.4 million in 2023, then rose by 4.1% to $873.8 million in 2024, then tumbled by 58.15% to $365.7 million in 2025.
  • The last three reported values for Cash from Financing Activities were $365.7 million (Q4 2025), -$1.6 million (Q3 2025), and $256.6 million (Q2 2025) per Business Quant data.